Plenary Lecture Special Lectures JPS-ASPET Lecture  by unknown
ABSTRACT
Plenary Lecture
Special Lectures
JPS-ASPET Lecture
2-PL Without searching, nothing
will be found―The Story of
Avermectin―
Satoshi Omura
Kitasato Institute for Life Sciences, Kitasato University
Avermectin is produced by an actinomycete, Streptomyces
avermectinius , which we discovered in a soil sample col-
lected in Japan. Avermectin and ivermectin, the dihydro de-
rivative of avermectin, arose from a pioneering international
collaboration between my group at The Kitasato Institute and
the Merck Research Laboratories in the United States. The
discovery of ivermectin was a unique advancement in animal
health, creating an extremely safe drug with a broad spec-
trum of internal and external antiparasitic activity.
Ivermectin has also provided immeasurable benefits in hu-
man health for a quarter of century, improving the lives of
hundreds of millions of the world’s poorest people in the proc-
ess. Thanks to a pioneering drug donation initiative, ivermec-
tin is being used, free of charge, in global programmes to
eliminate two devastating diseases that afflict mainly affect
poor communities in developing countries. Both diseases are
caused by filarial worms, Onchocerciasis arising from infec-
tion with Onchocerca volvulus and Lymphatic filariasis, one
of the most prevalent of tropical diseases, resulting from in-
fection with either Wuchereria bancrofti or Brugia malayi .
Ivermectin is so safe that tablets can be administered by non
medical people from affected communities following one or
two days training. Ivermectin is also being used to treat
strongyloidiasis, an intestinal parasitic disease found widely
in South East Asia and southern Japanese Islands, and to
treat scabies, which is estimated to infect more than 300 mil-
lion people globally each year.
1-SL-02 Pentameric ligand gated ion
channels functioning at the atomic
resolution
Pierre Jean Corringer
Pasteur Institute, Channel receptor Unit, CNRS
Pentameric channel receptors, including nicotinic acetylcholine, glycine and
GABAA receptors, play a key role in fast excitatory and inhibitory transmission
in the nervous system and are the target of numerous therapeutic and addictive
drugs. They carry several neurotransmitter binding sites which govern the
opening of a transmembrane ion channel. Extensively expressed in animals, they
were found in several bacteria, especially the homolog from the cyanobacteria
Gloeobacter violaceus (GLIC) which functions as a proton gated ion channel.
The simplified architecture of this archaic homologue, as well as its prokaryotic
origin, allowed solving its X ray structure in two closed and one open conforma-
tion. This suggests that channel opening occurs through symmetrical quaternary
twist and “blooming” motions, together with tertiary deformation, according to a
global transition that couples channel opening with reorganization of the binding
pockets for neurotransmitters and allosteric effectors. In addition, co crystalli-
zation of GLIC with allosteric inhibitors that are clinically used as general anes-
thetics reveals the mechanism of action at the membrane of these amphipatic
molecules and will help designing new drugs targeted to pentameric channel re-
ceptors. Further chimeric proteins between bacterial and human receptors was
exploited to collect high resolution structural data on clinically relevent recep-
tors. Altogether, these combined structural and functional data give insights into
the allosteric mechanisms operating in these integral membrane proteins, and
pave the way for the rational design of new classes of allosteric modulators.
Selected references
Bocquet et al, Nature , 457 : 111 4 (2009)
Nury et al, Nature , 469 : 428 31 (2011)
Prevost, M., et al Nat Struct Mol Biol . 19 : 642 9 (2012).
Sauguet et al, Proc Natl Acad Sci USA , 111 : 966 71 (2014)
Moraga et al, Proc Natl Acad Sci U S A. 112 : 2865 2870 (2015)S21-SL-01 Autophagy: an intracellular
degradation system
Noboru Mizushima
Dept. Mol. Biol., Grad. Sch. Med., Univ. Tokyo
Autophagy is a major degradation system in the cell. Intracel-
lular components are sequestered by autophagosomes and
then degraded upon fusion with lysosomes. Yeast genetic
studies have identified more than 40 autophagy-related
(ATG) genes. Many of these genes are conserved in higher
eukaryotes, which allow us to perform genetic analysis of
autophagy in mammals. Using autophagosome-indicator GFP-
LC3 mice and various autophagy-deficient mouse models, we
have shown that autophagy is important for maintenance of
the amino acid pool during starvation and neonatal periods,
preimplantation development as an amino acid supplying sys-
tem, and for intracellular protein quality control to prevent
neurodegeneration and tumorigenesis. We also identified a
human neurodegenerative disease, in which one of the core
autophagy genes is mutated. Thus, autophagy plays impor-
tant roles in various physiological and pathological processes.
We have been also investigating the molecular mechanisms of
autophagosome formation and the autophagosome-lysosome
fusion. Recently, we developed a novel fluorescent probe, us-
ing which autophagic degradation/flux can be measured in
cells and animals. This probe is also suitable for high
throughput screening, which would facilitate discovery of
autophagy-modulating drugs.
1-SL-03 Molecular mechanisms of
neural network reorganization after the
central nervous system injury
Toshihide Yamashita
Dept. Mol. Neurosci., Grad. Sch. Med., Osaka Univ.
Initial behavioral deficits resulting from brain injury are fre-
quently followed by spontaneous recovery of function. Al-
though reorganization of the neural network is considered to
contribute to this recovery, behavioral plasticity is not fully
understood. Furthermore, the molecular mechanism of this
phenomenon is poorly understood. Disorders of the central
nervous system, such as cerebrovascular diseases and cere-
brospinal trauma, often cause spatiotemporal changes in the
nervous system and in various biological systems, such as the
immune system and vascular system. We analyzed the
mechanism by which the spatiotemporal dynamics in those
biological systems control a series of processes. Additionally,
we aimed to elucidate the principles involved in the operation
of living organisms with neural network disorders within the
central nervous system by observing such disorders and
their functional recovery process with respect to the dynam-
ics of the entire biological system and by conducting a com-
prehensive analysis of the association between each system.
These immune cells, neovessels, and microglia may prove to
be drug targets for the treatment of CNS injuries, CNS in-
flammation, and neurodegenerative diseases.
1-SL-04 Structural Physiology is
headed for Pharmacology
Yoshinori Fujiyoshi
Grad. Sch. Pharm. Sci./CeSPI, Nagoya Univ.
The field of studies of structure and function of membrane
proteins was named“structural physiology”with a belief that
structure and physiological function are closely related. Util-
izing cryo-electron microscopes with helium-cooled specimen
stages that were developed through a personal motivation to
understand the functions of neural systems from a structural
point of view, the structures of membrane proteins can be
analyzed at a higher resolution than 3Å. As a typical exam-
ple, we could discriminate 8 water molecules in the water
channel AQP4, while their densities were blurred in the
structure analysed at 1.8 Å resolution by X-ray crystallogra-
phy. The structural and functional studies of AQP4 strongly
suggested that electron crystallography is very powerful
method for understanding physiological functions of mem-
brane proteins. AQP4 is predominantly expressed in the
brain and has important roles in maintaining brain homeosta-
sis, but is related with several brain pathologies including
brain edema and neuromyelitis optica. We confirmed acetazo-
lamide (AZA) inhibits the water permeability of AQP4 and
determined the structure of the complex. Heading for phar-
macology, structural physiology will become an important re-
search field for drug development.
3-SL-01 CELL BIOLOGICAL INSIGHTS
INTOVASCULAR FUNCTION
William C. Sessa
Yale University School of Medicine
Our laboratory is interested in endothelial cell biology and
signaling pertinent to cardiovascular function and disease.
The mechanosensitive enzyme, endothelial nitric oxide syn-
thase (eNOS) is situated in the plasma membrane of endothe-
lial cells and produces nitric oxide (NO) to regulate vasomo-
tion, angiogenesis and arterial remodeling of conduit and re-
sistance vessels. eNOS activity can be regulated by a multi
protein complex including the negative regulator caveolin 1
(Cav 1) and a positive regulator, the protein kinase, Akt. Al-
though components of this pathway are not critical for vascu-
lar development, each pathway is necessary for post natal
changes in permeability and angiogenesis. Data will be pre-
sented dissecting Cav 1 function in endothelium and new in-
sights into eNOS regulation.S2-SL-01 Regulation and therapeutic
application ofTGF β family signaling
Kohei Miyazono
Dept. Mol. Pathol., Grad. Sch. Med., Univ. Tokyo
TGF-β is widely known as a family of proteins that regulate
proliferation migration, and differentiation of cells. TGF-β in-
hibits many different types of cells, e.g. epithelial cells, endo-
thelial cells, and lymphocytes. TGF-β also induces expression
of various extracellular matrix proteins. More recently TGF-
β was shown to induce epithelial-mesenchymal transition
(EMT). Thus, TGF-β is involved in various diseases : it in-
duces fibrotic diseases, including glomerulonephritis and pul-
monary fibrosis. Anomalous activation of TGF-β signaling is
closely related to progression of certain connective tissue and
vascular diseases, including Marfan syndrome. TGF-β is also
involved in progression of cancer. Although perturbations of
the TGF-β signaling pathway results in progression of cancer
through escape from growth inhibitory activity of TGF-β,
EMT and other effects induced by TGF-β lead to progression
of cancer, i.e. invasion, metastasis, and resistance to chemo-
therapy. More recently, TGF-β was shown to regulate im-
mune function, and induce Treg cell differentiation. Clinical
use of TGF-β or its receptor inhibitors may thus be useful for
treatment of various diseases induced by over-activation of
TGF-β signaling.
3-SL-02 ANGIOGENESIS REVISITED:
ROLEAND (THERAPEUTIC)
IMPLICATIONS OF ENDOTHELIAL
METABOLISM
Peter Carmeliet
Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center,
Leuven Belgium Department of Oncology, KU Leuven
The past 40 years of research in the angiogenesis field have
focused on identifying genetic signals such as VEGF and
Notch, which determine vessel sprouting. However, the role
and therapeutic potential of targeting endothelial cell (EC)
metabolism have been largely overlooked. We have recently
reported that ECs are glycolysis addicted and that glycolysis
importantly co determine vessel sprouting downstream of
VEGF and other pro angiogenic signals. In addition, we docu-
mented that ECs are rather unique in utilizing fatty acid de-
rived carbons for the de novo synthesis of deoxyribonucleo-
tides for DNA synthesis during EC proliferation when ves-
sels sprout. Moreover, targeting (blocking) glycolysis and
fatty acid oxidation inhibit pathological angiogenesis and in-
duce tumor vessel normalization (thereby reducing metasta-
sis and improving chemotherapy), suggesting that these
metabolic pathways are new targets for anti angiogenic drug
development without evoking systemic side effects. Further-
more, lymphatic ECs differ from other EC subtypes in their
metabolic requirements for lymphangiogenesis. Since many
of these metabolic targets are pharmacologically druggable,
these metabolic pathways represent a new promising target
for therapeutic anti angiogenesis.3
3-SL-03 CHALLENGES IN
AZHEIMER’S DISEASE:
THE USE OF BRAIN IMAGING IN
TRANSLATIONAL DRUG DISCOVERY
Michela Gallagher
Johns Hopkins University
Addressing the burden of age related neurodegenerative dis-
ease is a great unmet need in the world today. Today we have
a clearer appreciation of how the molecular pathophysiology
of Alzheimer’s disease (AD) accumulates in specific brain cir-
cuits for more than a decade before symptomatic clinical
presentation. In amnestic Mild Cognitive Impairment (aMCI),
the earliest symptomatic phase of AD between normal aging
and a diagnosis of dementia, the hippocampus and entorhinal
cortex areas critical for memory formation are the first af-
fected by progressive neurodegeneration. Grounded in an un-
derstanding from basic research in laboratory animals, com-
putations that normally support episodic memory in those
circuits can be detected in healthy human subjects using
functional magnetic resonance imaging (fMRI). In transla-
tional research alterations in the computational properties of
those circuits observed in preclinical studies using animal
models match those observed in clinical studies of aMCI pa-
tients, leading to novel translational drug discovery for inter-
ventions in prodromal AD. This general approach has prom-
ise for developing biomarkers with brain imaging in other
neurological and psychiatric conditions to accelerate thera-
peutic discovery with translational success.
2-JAL POSTIVEALLOSTERIC
MODULATORS OF MUSCARINIC
ACETYLCHOLINE RECEPTORS FOR
TREATMENT OF CNS DISORDERS
P. Jeffrey Conn
Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology,
Vanderbilt Medical Center
Previous clinical and preclinical studies suggest that selective activators of
M1 and/or M4 subtypes of muscarinic acetylcholine receptors (mAChRs)
could provide a novel approach to improving cognitive function and reduc-
ing psychotic symptoms in patients suffering from Alzheimer’s disease and
schizophrenia. Unfortunately, previous efforts to develop selective ago-
nists of individual mAChR subtypes have not been successful and previous
compounds have failed in development because of adverse effects due to ac-
tivation of multiple mAChR subtypes. We have been highly successful in
developing selective positive allosteric modulators (PAMs) of both M1 and
M4 that have excellent properties for in vivo studies and potential develop-
ment as drug candidates. Interestingly, selective M1 PAMs have robust ef-
ficacy in enhancing synaptic plasticity in the hippocampus and the medial
prefrontal cortex (mPFC) in rodents. Furthermore, M1 selective PAMs in-
duce robust improvements in specific domains of cognitive function in ani-
mal models that are dependent of hippocampal and mPFC function. In con-
trast, highly selective M4 PAMs have robust antipsychotic like effects in
animal models. Furthermore, M4 PAMs reduce transmission at cortico
striatal synapses and normalized pathological increases in cortico striatal
transmission in mice that bear mutations that give rise to Huntington’s dis-
ease. Electrophysiology and genetic studies are providing important new
insights into the mechanisms by which M1 and M4 PAMs act in specific
cortical and midbrain circuits. These studies provide an exciting new ap-
proach to discovery of novel highly selective activators of individual
mAChR subtypes and suggest that subtype specific mAChR PAMs may
provide a novel approach for treatment of multiple CNS disorders.S3-SL-04 Regulation of neuronal
survival and function by endogenous
factors and natural products
Akinori Akaike
Dept. Cell. Pharmacol., Grad. Sch. Pharm. Sci., Nagoya Univ. Dept. Pharmacol.,
Grad. Sch. Pharm. Sci. Kyoto Univ.
Excitotoxicity and oxidative stress have been shown to con-
tribute to neuronal death associated with neurodegenerative
diseases. We hypothesized that distinct groups of substances
may regulate neuronal survival under pathological condi-
tions. Based on such an assumption, we explored neuroprotec-
tive substances in mammalian origin and isolated an atisane
derivative, serofendic acid, from fetal calf serum. This com-
pound inhibited generation of hydroxyl radical. We further
investigated substances preventing oxidative stress, and
found that green perilla extract activated Nrf2-ARE path-
way, which is known as a cellular defense system against oxi-
dative stress. The active ingredient responsible for the ARE
activity was identified as 2 ’, 3 ’ -dihydroxy-4 ’, 6 ’ -
dimethoxychalcone. As regeneration of neuronal projection
was expected to be a future treatment strategy for the dis-
eases, we established an in vitro model for quantitative
analysis of axonal outgrowth. Integrin α5 expressed in mesen-
cephalic dopaminergic neurons was important for their axons
to innervate striatal neurons. These findings suggest that
molecules with neuroprotective and/or neurite outgrowth
properties could have therapeutic applications in a range of
neurodegenerative diseases.4
